Study details
Enrolling now
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation
University of Florida
NCT IDNCT05800210ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 3.1 years
Ages
0.5–39
Locations
1 site in FL
What this study is about
This trial is testing a treatment to deplete alpha/beta T cells and CD19+ B cells from allogeneic stem cell transplants. The goal is to assess the safety, efficacy, and feasibility of this treatment approach for patients with certain types of cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Miltenyi CliniMACS Prodigy ® system
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Event-free survival, Overall survival
Devices
therapeutic
Body systems
Oncology